Inflammatory indices as prognostic markers in metastatic colorectal cancer patients treated with chemotherapy plus Bevacizumab.

ABSTRACT:

Background

Validated predictors of sensitivity or resistance to Bevacizumab (Bev) are not available, and Inflammatory Indexes (IIs) has been reported to be useful prognostic factors in various malignant solid tumours, including metastatic colorectal cancer (mCRC).

Objectives

To explore the prognostic value of IIs in mCRC patients treated with first-line chemotherapy plus Bev.

Design

One hundred and eighty-two patients diagnosed with mCRC and treated with first line chemotherapy plus Bev were considered for this prospective non-pharmacological study. Neutrophil, lymphocyte, platelet, aspartate transaminase (AST) and lactate dehydrogenase (LDH) tests were carried out at baseline and before each treatment cycle, according to clinical practice.

Methods

Pre-treatmen

SUBMITTER: Passardi A 

PROVIDER: S-EPMC10722949 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature